Boston Trust Walden Corp Increases Holdings in Amgen Inc. $AMGN

Boston Trust Walden Corp increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 17.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,552 shares of the medical research company’s stock after purchasing an additional 12,647 shares during the quarter. Boston Trust Walden Corp’s holdings in Amgen were worth $29,750,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Dogwood Wealth Management LLC raised its position in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in Amgen during the 4th quarter worth about $26,000. Tower View Wealth Management LLC grew its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the period. Finally, Manning & Napier Advisors LLC grew its holdings in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on AMGN shares. Jefferies Financial Group began coverage on Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Argus cut their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Morgan Stanley raised their price target on shares of Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research report on Tuesday, June 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $350.00 price objective on shares of Amgen in a report on Wednesday, April 8th. Finally, Guggenheim decreased their price objective on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $355.50.

Amgen Price Performance

Shares of AMGN opened at $374.15 on Friday. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The stock has a fifty day simple moving average of $342.43 and a two-hundred day simple moving average of $347.93. The company has a market capitalization of $201.93 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 3.68 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.39 EPS for the current year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.